Company
Am Regent
Last checked: Nov 20, 2026Source: Drugs@FDA, ClinicalTrials.gov
NDAs and BLAs
9
7 still marketed
Novel approvals
0
Approvals since 2021
4
Originals and new uses
Phase 3 trials
0
Registered, any status
Trials by phase
All registered drug and biologic trials with this lead sponsor, any status. A public view of the pipeline.
Recent approvals
Originals and efficacy supplements, newest first.
- Injectafer new use May 31, 2023
- Paclitaxel approved Jul 27, 2022
- Injectafer new use Nov 19, 2021
- Injectafer new use Apr 28, 2021
- Vasopressin approved Aug 3, 2020
- Multrys approved Jul 2, 2020
- Zinc Sulfate approved Jul 18, 2019
- Selenious Acid approved Priority reviewApr 30, 2019
- Injectafer new use Priority reviewJan 26, 2018
- Injectafer approved Jul 25, 2013
Drugs in development (0)
Investigational drugs, not yet FDA-approved, in this company's active or recent Phase 2 and 3 trials. Phase 3 first.
No investigational drugs in Phase 2 or 3 trials under this sponsor name.
Recruiting Phase 3 trials
Largest first.
No recruiting Phase 3 trials under this sponsor name.
Marketed drugs (7)
Newest FDA action first.
- Injectafer Ferric Carboxymaltose · 2013
- Venofer Iron Sucrose · 2000
- Multrys Cupric Sulfate, Manganese Sulfate, Selenious Acid, Zinc Sulfate · 2020
- Paclitaxel Paclitaxel · 2022
- Selenious Acid Selenious Acid · 2019
- Zinc Sulfate Zinc Sulfate · 2019
- Vasopressin Vasopressin · 2020
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.